Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are readily detected in pancreatic tumors isolated from PDAC patien...

Full description

Bibliographic Details
Main Authors: Abrams, S., Lertpiriyapong, K., Yang, L., Martelli, A., Cocco, L., Ratti, S., Falasca, Marco, Murata, R., Rosalen, P., Lombardi, P., Libra, M., Candido, S., Montalto, G., Cervello, M., Steelman, L., McCubrey, J.
Format: Journal Article
Published: Pergamon 2018
Online Access:http://hdl.handle.net/20.500.11937/69662

Internet

http://hdl.handle.net/20.500.11937/69662

Similar Items